hVIVO (LON:HVO) Shares Up 13% – Here’s What Happened

hVIVO plc (LON:HVO) shares rose 13% on Tuesday . The stock traded as high as GBX 8 ($0.11) and last traded at GBX 7.80 ($0.10). Approximately 9,588,585 shares were traded during mid-day trading, an increase of 223% from the average daily volume of 2,969,923 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analyst Ratings Changes

Several analysts have recently commented on the stock. Peel Hunt restated an “add” rating and set a GBX 21 price objective on shares of hVIVO in a research report on Tuesday, July 29th. Shore Capital decreased their price objective on shares of hVIVO from GBX 35 to GBX 25 and set a “buy” rating on the stock in a research report on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of GBX 23.

hVIVO Stock Up 2.6%

The stock has a market capitalization of £54.98 million, a P/E ratio of 1,038.96 and a beta of 0.97. The company’s 50-day moving average price is GBX 9.24 and its 200 day moving average price is GBX 11.96. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61.

hVIVO (LON:HVO) last posted its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, equities analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.